Drug-resistant tuberculosis clinical trials: Proposed core research definitions in adults

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 3, 2016, Pages 290-294

  Furin, J ^a   Alirol, E ^b   Allen, E ^c   Fielding, K ^c   Merle, C ^c   Abubakar, I ^d   Andersen, J ^e   Davies, G ^f   Dheda, K ^g   Diacon, A ^h   Dooley, K E ⁱ   Dravnice, G ^j   Eisenach, K ^k   Everitt, D ^l   Ferstenberg, D ^m   Goolam Mahomed, A ⁿ   Grobusch, M P ^o   Gupta, R ^p   Harausz, E ^a   Harrington, M ^q   Horsburgh, C R ^r   Lienhardt, C ^s   McNeeley, D ^t   Mitnick, C D ^u   Nachman, S ^v   Nahid, P ^w   Nunn, A J ^x   Phillips, P ^x   Rodriguez, C ^y   Shah, S ^u   Wells, C ^p   Thomas Nyang'wa, B ^b   Du Cros, P ^b   more..

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Manson Unit Médicins Sans Frontières   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h UNIVERSITY OF STELLENBOSCH   (South Africa)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

^k UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^l Global Alliance for TB Drug Development   (United States)

^m Sequella   (United States)

ⁿ UNIVERSITY OF LIMPOPO   (South Africa)

^o UNIVERSITY OF AMSTERDAM   (Netherlands)

^p Otsuka USA ^*  (United States)

^q Treatment Action Group   (United States)

^r BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^s WORLD HEALTH ORGANIZATION   (Switzerland)

^t Medical Service Corporation International   (United States)

^u HARVARD MEDICAL SCHOOL   (United States)

^v STONY BROOK UNIVERSITY   (United States)

^w UNIVERSITY OF CALIFORNIA   (United States)

^x MEDICAL RESEARCH COUNCIL   (United Kingdom)

^y P D HINDUJA NATIONAL HOSPITAL   (India)

more..

Author keywords

Definitions; Drug resistant tuberculosis; Research

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; CAUSE OF DEATH; CLINICAL RESEARCH; CLINICAL STUDY; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; FOLLOW UP; HUMAN; LUNG TUBERCULOSIS; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT INFECTION; SPUTUM CULTURE; TREATMENT FAILURE; TREATMENT OUTCOME; ADULT; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; METHODOLOGY; MYCOBACTERIUM TUBERCULOSIS; STANDARDS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ADULT; ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RESEARCH DESIGN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84958522574     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.15.0490     Document Type: Article

References (12)

1. World Health Organization. Global tuberculosis report, 2014. WHO/HTM/TB/2014.08. Geneva, Switzerland: WHO, 2014.
2. Zumla A, Schito M, Maeurer M. Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers and vaccines. Lancet Infect Dis 2014; 14: 267-269.
3. Zumla A, Gillespie S, Hoelscher M, et al. New anti-tuberculosis drugs, regimens, and adjunct therapies: needs, advances and future prospects. Lancet Infect Dis 2014; 24: 49-62.
4. Brigden G, Nyang'wa B T, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ 2013; 92: 68-74.
5. US Food and Drug Administration. Guidance for industry pulmonary tuberculosis: developing drugs for treatment. Draft guidance.Washington DC, USA: FDA, 2013. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm373580.pdf Accessed January 2016.
6. Vaismoradi M, Turunen H, Bondas T. Content analysis and thematic analysis: implications for conducting a qualitative descriptive trial. Nurs Health Sci 2013; 15: 398-405.
7. Donomae I, Yamamoto K. Clinical evaluation of ethambutol in pulmonary tuberculosis. Ann N Y Acad Sci 1966; 135: 849-881.
8. Mitchison D A, Keyes A B, Edwards E A, Ayuma P, Byfield S P, Nunn A J. Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in Africa. Tubercle 1980; 61: 135.
9. Podewils L J, Gler M T S, Quelapio M I, ChenM P. Patterns of treatment interruption among patients with multidrug-resistant TB (MDR-TB) and association with interim and final treatment outcomes. PLOS ONE 2013; 8: e70064.
10. Phillips P, Crook A, Nunn A. The evolution of and challenges in defining the clinical endpoint in tuberculosis treatment trials with non-inferiority designs. Trials 2011; 12 (Suppl 1): A31.
11. Council for International Organizations of Medical Sciences. Management of safety information from clinical trials: report of CIOMS Working Group 4. Geneva, Switzerland: CIOMS, 2005.
12. Johnson J, Thiel B. Time until relapse in tuberculosis treatment trials: implications for phase 3 trial design. Am J Respir Crit Care Med 2012; 186: 464.